Migraine Trial, Recruiting NCT06503848 Sponsor: Hospital Universitari Vall d'Hebron Research Institute Condition: Migraine
Back to Migraine

Migraine Trial, Recruiting

NCT06503848
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with migraine (with or without aura) according to recognised international headache diagnostic standards
  • People who experience fewer than 8 migraine days per month
  • People who are able to read, write, and understand instructions
  • People who have access to the internet and an email address
  • People who are willing to sign a consent form agreeing to take part

Who may not be able to join:

  • People who are currently taking preventive (ongoing) medication specifically for migraine
  • People who are currently taking any medication that affects the central nervous system (brain and spinal cord)
  • People who have a serious physical or mental health condition
  • People who have a heart, blood vessel, or liver disease
  • People who are pregnant or breastfeeding
  • People for whom triptan medications (a common type of migraine treatment) are not medically suitable
  • People who experience severe migraine attacks that have not previously responded to triptans or anti-inflammatory pain relievers such as ibuprofen

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Marta Torres-Ferrús, PhD, Hospital Universitari Vall d'Hebron, Headache & Neurological Pain Research Group

Phone: (+34)934893000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Hospital Universitari Vall d'Hebron Research Institute
Registry
ClinicalTrials.gov
Start date
25 January 2024
Est. completion
1 December 2024

Where this trial is recruiting

🇪🇸 Spain

Primary endpoints

Response to sumatriptan

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov